Abbott Laboratories is a renowned healthcare company with a strong business model focused on providing a diverse range of medical products, diagnostics, nutritional supplements, and pharmaceuticals. By combining technological advancements with innovative research, Abbott aims to enhance the quality of life for individuals worldwide. With a comprehensive portfolio spanning diverse healthcare sectors, including diagnostics, nutrition, diabetes care, medical devices, and branded generic pharmaceuticals, Abbott Laboratories strives to improve patient outcomes and deliver sustainable growth. Through its commitment to scientific excellence and dedication to meeting evolving healthcare needs, Abbott Laboratories has established itself as a trusted leader in the global healthcare industry.

Abbott Laboratories is primarily active in the healthcare industry.

The main competitors of Abbott Laboratories in the market are Johnson & Johnson, Pfizer, and Roche Holding AG.

Abbott Laboratories is a renowned American healthcare company, known for providing a diverse range of medical, pharmaceutical, and nutritional products. Founded in 1888 by Dr. Wallace C. Abbott, the company initially focused on producing pharmaceuticals, including the widely successful alkaloid-based pain reliever, Abbott's ABC Liniment. Over the years, Abbott Laboratories has expanded its portfolio, venturing into areas such as diagnostics, medical devices, and nutrition. The company's commitment to innovation is evident through breakthroughs like the development of the first HIV blood-screening test. Today, Abbott Laboratories continues to play a crucial role in improving health outcomes worldwide, with its cutting-edge technology and a focus on delivering quality healthcare solutions.

Abbott Laboratories has achieved several significant milestones throughout its history. One major milestone was the development and commercialization of the first-ever HIV blood screening test, which greatly contributed to safer transfusions and the prevention of the spread of HIV. Additionally, Abbott Laboratories introduced breakthrough medical devices, such as the FreeStyle® Libre system, a continuous glucose monitoring system for diabetes management. The company also played a crucial role in the fight against COVID-19 by developing rapid diagnostic tests for the virus. Furthermore, Abbott Laboratories has consistently been recognized for its commitment to innovation and sustainability, making it a leading healthcare company globally.

Abbott Laboratories is primarily present in multiple countries and regions worldwide. The company operates in more than 160 countries, including the United States, Canada, Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global footprint, Abbott Laboratories has established itself as a leading healthcare company in various markets, delivering innovative medical products, diagnostics, nutritionals, and pharmaceuticals to improve people's health and well-being.

Abbott Laboratories is committed to its core values of putting patients first, serving customers with innovative solutions, and operating with integrity in all aspects of its business. The company's corporate philosophy centers around improving life through the development of groundbreaking technologies and products. Abbott Laboratories prides itself on its dedication to delivering reliable healthcare solutions, fostering collaboration with healthcare professionals, and investing in research and development to address unmet medical needs. With a focus on providing high-quality and accessible healthcare options, Abbott Laboratories strives to create positive impacts in communities worldwide through its diverse portfolio of medical devices, diagnostics, nutrition, and pharmaceutical products.

Analysts currently set an average price target of 136,02 USD for the Abbott Laboratories stock (median: 137,70 USD), implying +28,8 % versus the latest price. The consensus is based on 35 analyst ratings.

Abbott Laboratories Analytikers kursmål 2026

35 analysts currently rate the Abbott Laboratories stock: 25 recommend buying, 10 holding and 0 selling. For 2026, analysts expect Abbott Laboratories to generate revenue of 50,29 Mrd. USD and earnings per share of 5,51 USD.

Abbott Laboratories Analytikers kursmål 2026

Converted at the current exchange rate, the Abbott Laboratories share trades at 92,78 EUR (105,59 USD).

The Abbott Laboratories share (ABT) is listed on 9 stock exchanges, including: NYSE (ABT), XETRA (ABL.DE), Frankfurt (ABL.F), München (ABL.MU), Düsseldorf (ABL.DU), Hamburg (ABL.HM), London (0Q15.L), SIX (Zürich) (ABT.SW).

Abbott Laboratories is a global company specializing in the development, manufacturing, and marketing of health products and services. Its business model is divided into different divisions that focus on the needs of patients, doctors, and healthcare systems. The divisions of Abbott Laboratories include Diagnostics, Medical Devices, Nutrition, and Pharmaceutical. The company aims to continuously develop innovative technologies and products to improve healthcare, and it offers a wide range of services and support programs for patients. Abbott Laboratories has established a strong market position and global presence in over 160 countries since its establishment in 1888. It also pursues a successful acquisition strategy to expand its product portfolio, such as the acquisition of St. Jude Medical in 2017 to enhance its cardiovascular products and services. Overall, Abbott Laboratories aims to improve healthcare and meet the needs of patients, doctors, and healthcare systems through its comprehensive strategy focused on developing innovative products, expanding into new markets, and increasing efficiency.

forventet omsetningen for Abbott Laboratories er 50,29 Mrd. USD. Denne verdien er basert på nåværende regnskapstall og gjenspeiler selskapets forretningsutvikling.

forventet gevinsten for Abbott Laboratories er 9,63 Mrd. USD. Nettoresultatet viser selskapets lønnsomhet etter fradrag av alle kostnader.

Pris-til-inntjening-ratioen (P/E) for Abbott Laboratories er for tiden 19,15. P/E-ratioen sammenligner dagens aksjekurs med inntjening per aksje og hjelper investorer med å vurdere verdisetningen av Abbott Laboratories-aksjen.

Pris-til-salg-ratioen (P/S) for Abbott Laboratories er for tiden 3,67. P/S-ratioen sammenligner markedskapitalisering med årlig omsetning og fungerer som en verdisettelsesindiktor for Abbott Laboratories-aksjen.

Eulerpool Quality Score for Abbott Laboratories er 6/10.

ISIN for Abbott Laboratories er US0028241000. ISIN (International Securities Identification Number) er en globalt unik identifikator for verdipapirer.

WKN for Abbott Laboratories er 850103. WKN (Wertpapierkennnummer) er et seks-sifret tysk verdipapirnummer.

Tickeren for Abbott Laboratories er ABT. Tickersymbolet brukes til å handle Abbott Laboratories-aksjer på børsen.

I løpet av de siste 12 månedene betalte Abbott Laboratories utbytte på 2,36 USD . Dette tilsvarer en utbytteavkastning på ca. 2,24 %. For de kommende 12 månedene forventes Abbott Laboratories å betale utbytte på 2,76 USD.

Utbytteavkastningen til Abbott Laboratories er for tiden 2,24 %.

Abbott Laboratories betaler utbytte som utdeles i månedene , , , .

Abbott Laboratories betalte utbytte hvert år de siste 52 årene.

For de kommende 12 månedene forventes utbytte på 2,76 USD. Dette tilsvarer en utbytteavkastning på 2,61 %.

Abbott Laboratories er klassifisert i sektoren 'Helse'.

For å motta det siste utbyttet fra Abbott Laboratories fra på 0,63 USD, måtte du ha aksjen i porteføljen før ex-datoen den .

Det siste utbyttet ble utbetalt den .

I året 2025 ble det utdelt 2,24 USD i utbytte fra Abbott Laboratories.

Utbyttene fra Abbott Laboratories utdeles i USD.